90 related articles for article (PubMed ID: 15238776)
1. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy.
Barrón Y; Cole SR; Greenblatt RM; Cohen MH; Anastos K; DeHovitz JA; Delapenha R; Gange SJ
AIDS; 2004 Jul; 18(11):1579-84. PubMed ID: 15238776
[TBL] [Abstract][Full Text] [Related]
2. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
3. [Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].
Pérez-Hoyos S; Ferreros I; Hernán MA;
Gac Sanit; 2007; 21(1):76-83. PubMed ID: 17306191
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
6. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
[TBL] [Abstract][Full Text] [Related]
7. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
9. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
Moore DM; Hogg RS; Yip B; Craib K; Wood E; Montaner JS
HIV Med; 2006 Sep; 7(6):383-8. PubMed ID: 16903983
[TBL] [Abstract][Full Text] [Related]
10. Mortality and its predictors among highly active antiretroviral therapy naive hiv-infected individuals: data from prospective cohort study in Ukraine.
Zhyvytsia D
Georgian Med News; 2014; (232-233):69-74. PubMed ID: 25214276
[TBL] [Abstract][Full Text] [Related]
11. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
12. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia.
Ebissa G; Deyessa N; Biadgilign S
AIDS Care; 2015; 27(6):723-30. PubMed ID: 25599414
[TBL] [Abstract][Full Text] [Related]
13. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
14. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
[TBL] [Abstract][Full Text] [Related]
15. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
Cole SR; Jacobson LP; Tien PC; Kingsley L; Chmiel JS; Anastos K
Am J Epidemiol; 2010 Jan; 171(1):113-22. PubMed ID: 19934191
[TBL] [Abstract][Full Text] [Related]
16. Structural accelerated failure time models for survival analysis in studies with time-varying treatments.
Hernán MA; Cole SR; Margolick J; Cohen M; Robins JM
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):477-91. PubMed ID: 15660442
[TBL] [Abstract][Full Text] [Related]
17. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study.
Palella FJ; Armon C; Buchacz K; Cole SR; Chmiel JS; Novak RM; Wood K; Moorman AC; Brooks JT;
Ann Intern Med; 2009 Jul; 151(2):73-84. PubMed ID: 19620160
[TBL] [Abstract][Full Text] [Related]
18. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
[TBL] [Abstract][Full Text] [Related]
19. Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort.
Perez-Hoyos S; Rodríguez-Arenas MA; García de la Hera M; Iribarren JA; Moreno S; Viciana P; Peña A; Gómez Sirvent JL; Saumoy M; Lacruz J; Padilla S; Oteo JA; Asencio R; Del Amo J;
J Womens Health (Larchmt); 2007 Sep; 16(7):1052-61. PubMed ID: 17903082
[TBL] [Abstract][Full Text] [Related]
20. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.
de Martino M; Tovo PA; Balducci M; Galli L; Gabiano C; Rezza G; Pezzotti P
JAMA; 2000 Jul; 284(2):190-7. PubMed ID: 10889592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
